News

Roche's phase III IMmotion151 study of Tecentriq & Avastin to treat advanced/metastatic RCC meets co-primary endpoint

Madrigal Pharma inks exclusive global license agreement with CSPC Pharma for SYH2086, a preclinical oral small molecule GLP-1 receptor agonist

Conshohocken, Pa.

Friday, August 1, 2025, 15:00 Hrs [IST]

Madrigal Pharmaceuticals, Inc., a biopharmaceutical company focused on delivering novel therapeutics for MASH, announced that it has entered into an exclusive global license agreement with CSPC Pharmaceutical

To access the full article, please log in or subscribe.

Pharma Services

Tenders & Projects

Tenders & Enquires Pharma Projects

Corporate

Company Profile Corporate Results Corporate X-ray Pharmabiz Studies of Top Companies

US FDA Update

US FDA: ANDA US FDA: Warnings US FDA: Approved NMEs US FDA: Approved NMEs US FDA: REFUSAL

Export & Import

Drug Export Procedures Drug Units With WHO GMP Certification Pharma Export Data Import Reg. Update

Pharma Laws & Documents

Notifications Pharma Regulations Patent Laws and Amendments Patent Scan Documents New Drug Approvals Notified Prices

Labs & Govt Bodies

Govt Recognised In-House R&D Units AICTE Boards & Committees List of Indian CROs List of CROs (International) Govt & approved labs of India List of State Drugs Controllers